Full Press Release Details
Kamada to Announce Second Quarter and First
Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024
Rehovot, Israel, and Hoboken, NJ, August 7,
2024 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed
products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release
financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday,
Kamada management will host an investment community
conference call on Wednesday, August 14 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested
parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263
(International) using conference ID 13747542. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1678713&tp_key=b3f21d48c3
will also be archived for 90 days on the Company's website at www.kamada.com.
Kamada Ltd. (the "Company") is a commercial
stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in
the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative
development pipeline targeting areas of significant unmet medical need. The Company's strategy is focused on driving profitable
growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical
fields. The Company's commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB ,
CYTOGAM , WINRHO SDF , VARIZIG , HEPAGAM B and GLASSIA , as well as KAMRAB , KAMRHO (D) and two types of
equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic
partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India Australia
and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli
market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During
recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines
Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA
licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the
manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company's commercial operation, it invests in research and development
of new product candidates. The Company's leading investigational product is an inhaled AAT for the treatment of AAT deficiency,
for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial.
FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company's controlling shareholder, beneficially owning
approximately 38% of the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC